Rasna Therapeutics IncOOTC RASP Stock Report

Rasna Therapeutics, Inc. is a biotechnology company, which engages in the development of therapeutics for the treatment of leukemia and lymphoma diseases. The company is headquartered in New York City, New York and currently employs 0 full-time employees. The company went IPO on 2014-03-28. The firm is engaged in developing therapeutics to address the unmet need for acute myeloid leukemia (AML), and other forms of leukemia and lymphoma. Its clinical program is based around three druggable intervention points with potential to improve safety and efficacy of AML therapies. The firm develops small molecule drug candidates targeting two genes: nucleophosmin-1 (NPM1) and lysine specific demethylase-1 (LSD1). Its product candidates include RASP-201 and RASP-301. Its the lead reversible LSD-1 candidate, RASP-201 is an orally dosed, selective reversible inhibitor of lysine-specific demethylase, or LSD1, a pathway that blocks differentiation and confers a poor prognosis to AML. The firm's product candidate, RASP-301, is an oral, small molecule inhibitor that in preclinical studies to disrupt NPM1 oligomerization and has the potential to treat refractory AML with reduced toxicity at low dose levels.